Hongde Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hongde Xu has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Yongchun Li
Zhengzhou University, Zhengzhou, P. R. China
5 shared publications- Yuan-Yuan Qi
Department of Nephrology, the First Affiliated Hospital of Zhengzhou University
4 shared publications Chen Liu
Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Institute of Nephrology, Zhengzhou University, Zhengzhou, P. R. China
3 shared publications- Chunli Wu
School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China
3 shared publications - Zhanzheng Zhao
Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, China
3 shared publications - Cheng-Yun Jin
School of Pharmaceutical Science, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou 450001, China
2 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Springer Nature in Arthritis Research & Therapy
GLP-1 receptor agonists as novel renoprotective agents in lupus nephritis
Background: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus and a major cause of chronic kidney disease (CKD). Despite advances with immunosuppressive therapy, many patients continue to develop progressive renal impairment. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for diabetes and CKD, have shown renoprotective effects, but their potential in LN remains undefined. Methods: We evaluated the renoprotective effects of liraglutide in lupus-prone MRL/lpr mice using functional, histopathological, and molecular analyses integrated with single-nucleus transcriptomics. Mechanistic studies involved ferroptosis inhibition and pharmacological blockade of cAMP signaling. To provide clinical context, we also describe a patient with class III + V LN who initiated semaglutide during immunosuppressant tapering. Results: In lupus-prone MRL/lpr mice, liraglutide reduced proteinuria, improved renal function, and ameliorated histopathological injury without altering systemic autoantibody levels. Single-nucleus transcriptomics revealed cell type–specific remodeling, including suppression of inflammatory and metabolic pathways in podocytes, mesangial, and tubular cells, alongside signatures of tubular repair. Liraglutide treatment was associated with reduced immune infiltration, NF-κB and NLRP3 signaling, fibrosis, oxidative stress, and ferroptosis-related changes, as well as enhanced autophagy. Ferroptosis inhibition recapitulated several protective effects of liraglutide, whereas cAMP blockade attenuated its effects on renal function, inflammation, oxidative stress, and ferroptosis-related parameters. In a single clinical observation, proteinuria decreased following semaglutide initiation during ongoing immunosuppressive management; however, no causal inference can be made from this case. Conclusions: GLP-1RAs improved renal outcomes in lupus-prone mice in association with anti-inflammatory, antioxidant, and reduced ferroptosis-related changes. Pharmacological experiments further support the involvement of cAMP signaling and ferroptosis in these renoprotective effects.
- 14 October 2026
- Published by Springer Nature in Arthritis Research & Therapy
Open AccessGLP-1 receptor agonists as novel renoprotective agents in lupus nephritis
Background: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus and a major cause of chronic kidney disease (CKD). Despite advances with immunosuppressive therapy, many patients continue to develop progressive renal impairment. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for diabetes and CKD, have shown renoprotective effects, but their potential in LN remains undefined. Methods: We evaluated the renoprotective effects of liraglutide in lupus-prone MRL/lpr mice using functional, histopathological, and molecular analyses integrated with single-nucleus transcriptomics. Mechanistic studies involved ferroptosis inhibition and pharmacological blockade of cAMP signaling. To provide clinical context, we also describe a patient with class III + V LN who initiated semaglutide during immunosuppressant tapering. Results: In lupus-prone MRL/lpr mice, liraglutide reduced proteinuria, improved renal function, and ameliorated histopathological injury without altering systemic autoantibody levels. Single-nucleus transcriptomics revealed cell type–specific remodeling, including suppression of inflammatory and metabolic pathways in podocytes, mesangial, and tubular cells, alongside signatures of tubular repair. Liraglutide treatment was associated with reduced immune infiltration, NF-κB and NLRP3 signaling, fibrosis, oxidative stress, and ferroptosis-related changes, as well as enhanced autophagy. Ferroptosis inhibition recapitulated several protective effects of liraglutide, whereas cAMP blockade attenuated its effects on renal function, inflammation, oxidative stress, and ferroptosis-related parameters. In a single clinical observation, proteinuria decreased following semaglutide initiation during ongoing immunosuppressive management; however, no causal inference can be made from this case. Conclusions: GLP-1RAs improved renal outcomes in lupus-prone mice in association with anti-inflammatory, antioxidant, and reduced ferroptosis-related changes. Pharmacological experiments further support the involvement of cAMP signaling and ferroptosis in these renoprotective effects.
- RetractionOpen Access
- 19 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16  (1) , 2195
Retraction Note: A novel chalcone derivative S17 induces apoptosis through ROS dependent DR5 up-regulation in gastric cancer cells
- 19 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16  (1) , 2195
RetractionOpen AccessRetraction Note: A novel chalcone derivative S17 induces apoptosis through ROS dependent DR5 up-regulation in gastric cancer cells
- Open Access
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1732243
Dual blockade of DPP-4 and CXCL12/CXCR4 axes synergistically protects podocytes in lupus nephritis
Background: Lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), is characterized by podocyte injury that contributes to disease progression. Dipeptidyl peptidase-4 (DPP-4) inhibitors, though developed for diabetes, have shown renoprotective potential. However, DPP-4 inhibition may elevate CXCL12/CXCR4 signaling, a pathway implicated in LN pathogenesis. This study aimed to determine whether dual DPP-4 and CXCL12/CXCR4 blockade confers enhanced renal protection in LN. Methods: MRL/lpr lupus-prone mice were treated with the DPP-4 inhibitor linagliptin, either alone or in combination with the CXCL12/CXCR4 axis antagonist AMD3100. We evaluated renal function, histopathology, podocyte structure, and markers of oxidative stress, fibrosis, and inflammation. In vitro assays using DPP4-knockout podocytes were also performed to elucidate underlying mechanisms. Results: DPP4-deficient podocytes exhibited elevated CXCL12/CXCR4 expression and modest nephrin upregulation. Co-treatment with AMD3100 further increased nephrin expression compared to linagliptin alone. In vivo , linagliptin monotherapy reduced proteinuria and serum creatinine but also increased CXCL12/CXCR4 expression. Combined therapy significantly decreased proteinuria, serum creatinine, anti-dsDNA, and ANA titers. Histological analysis showed reduced mesangial proliferation and interstitial inflammation. Transmission electron microscopy and immunostaining demonstrated improved podocyte foot process integrity and upregulation of nephrin and podocin. Dual blockade also reduced renal oxidative stress (DHE, NOX4), fibrosis markers (α-SMA, fibronectin), and inflammatory mediators (NF-κB p65, NLRP3). Conclusion: Combined DPP-4 and CXCL12/CXCR4 axis inhibition synergistically enhanced podocyte protection and attenuated renal inflammation, fibrosis, and oxidative stress in lupus nephritis. These findings support dual blockade as a promising therapeutic strategy for LN.
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1732243
Open AccessDual blockade of DPP-4 and CXCL12/CXCR4 axes synergistically protects podocytes in lupus nephritis
Background: Lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), is characterized by podocyte injury that contributes to disease progression. Dipeptidyl peptidase-4 (DPP-4) inhibitors, though developed for diabetes, have shown renoprotective potential. However, DPP-4 inhibition may elevate CXCL12/CXCR4 signaling, a pathway implicated in LN pathogenesis. This study aimed to determine whether dual DPP-4 and CXCL12/CXCR4 blockade confers enhanced renal protection in LN. Methods: MRL/lpr lupus-prone mice were treated with the DPP-4 inhibitor linagliptin, either alone or in combination with the CXCL12/CXCR4 axis antagonist AMD3100. We evaluated renal function, histopathology, podocyte structure, and markers of oxidative stress, fibrosis, and inflammation. In vitro assays using DPP4-knockout podocytes were also performed to elucidate underlying mechanisms. Results: DPP4-deficient podocytes exhibited elevated CXCL12/CXCR4 expression and modest nephrin upregulation. Co-treatment with AMD3100 further increased nephrin expression compared to linagliptin alone. In vivo , linagliptin monotherapy reduced proteinuria and serum creatinine but also increased CXCL12/CXCR4 expression. Combined therapy significantly decreased proteinuria, serum creatinine, anti-dsDNA, and ANA titers. Histological analysis showed reduced mesangial proliferation and interstitial inflammation. Transmission electron microscopy and immunostaining demonstrated improved podocyte foot process integrity and upregulation of nephrin and podocin. Dual blockade also reduced renal oxidative stress (DHE, NOX4), fibrosis markers (α-SMA, fibronectin), and inflammatory mediators (NF-κB p65, NLRP3). Conclusion: Combined DPP-4 and CXCL12/CXCR4 axis inhibition synergistically enhanced podocyte protection and attenuated renal inflammation, fibrosis, and oxidative stress in lupus nephritis. These findings support dual blockade as a promising therapeutic strategy for LN.
- Open Access
- 10 October 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1705678
Editorial: Drug development for pancreatic cancer: novel targets, drug candidates and mechanisms
Pancreatic ductal adenocarcinoma (PDAC), the most prevalent subtype of pancreatic cancer, constitutes approximately 90% of all pancreatic cancer cases. It is recognized as one of the most aggressive malignancies globally, with a five-year survival rate persistently around 12%[1]. The absence of early specific symptoms and effective screening methods results in over 80% of patients being diagnosed at an advanced stage, frequently with local invasion or distant metastasis, thereby significantly limiting treatment options and contributing to a poor prognosis[2]. This challenging scenario highlights the urgent necessity to enhance our understanding of the biological mechanisms underlying PDAC and to develop innovative therapeutic strategies. While engineered T cell therapy has demonstrated significant success in treating hematologic malignancies, its application in PDAC remains fraught with substantial challenges[3]. These include an immunosuppressive microenvironment, tumor antigen heterogeneity, and inadequate T cell infiltration coupled with functional exhaustion. Moreover, PDAC treatment is hindered by several factors: a highly heterogeneous genomic landscape, a complex tumor microenvironment (TME), a persistently immunosuppressive state, and metabolic reprogramming mechanisms, all of which contribute to therapy resistance. Addressing these challenges necessitates interdisciplinary collaboration and the development of integrated, multi-dimensional interventional strategies—this is the primary research focus that this Research Topic seeks to advance. This collection of studies presents four pioneering investigations that illuminate the biological characteristics and therapeutic strategies of PDAC from diverse perspectives. These studies not only advance the understanding of disease mechanisms but also investigate novel interventions with translational potential, including immune cell engineering, natural product screening, and epigenetic regulation. Notably, the research conducted by Zhu et al. transcends traditional αβ T cell approaches by concentrating on the application of γδ T cells and natural killer T (NKT) cells in PDAC immunotherapy. Utilizing a mesothelin/CD3 bispecific antibody (BsAb), the authors demonstrate that these cells exhibit significantly enhanced tumor-killing activity both in vitro and in vivo, while substantially reducing the release of inflammatory cytokines such as IL-6 and IL-1β. This reduction in cytokine release mitigates the toxicities commonly associated with conventional αβ T cell-based therapies. Consequently, this study broadens the spectrum of cellular immunotherapy options and provides new pathways for enhancing treatment safety. Chen et al. tackle the issue of CAR-T cell exhaustion in PDAC through a novel strategy involving the co-expression of the IL-15/IL-15Rα complex (IL15C). This approach activates the JAK3/STAT5 signaling pathway, thereby significantly enhancing the proliferative capacity and anti-apoptotic characteristics of NKG2D-CAR T cells. The engineered cells exhibit a marked reduction in the expression of exhaustion markers, such as PD-1 and TIM-3, and preferentially differentiate into central memory T cells, leading to more sustained tumor control in vivo. This innovative strategy offers a valuable framework for optimizing CAR-T cell therapy in the context of solid tumors. In parallel, although Shao et al. conducted their investigation within a lung cancer model, their comprehensive research methodology offers substantial insights for PDAC drug development. By integrating network pharmacology, molecular docking, and functional validation, the researchers elucidate the anti-tumor mechanisms of cyclomorusin, an active compound derived from the traditional Chinese medicine Cortex Mori. This compound exerts its effects by inhibiting the PI3K/AKT/mTOR signaling pathway. The study highlights the contemporary scientific relevance of compounds derived from traditional medicine and provides a theoretical basis for the development of natural products targeting pancreatic ductal adenocarcinoma. Wang et al. explore the role of protein SUMOylation in PDAC and develop a prognostic scoring system (Sscore) based on SUMO substrate-encoding genes, including CDK1, AHNAK2, and SAFB. This model demonstrates efficacy in predicting patient survival and shows associations with genomic instability, immune infiltration, and drug sensitivity. Notably, through functional experiments, the authors identify SAFB2 as a novel tumor suppressor that impedes PDAC progression by inhibiting the Wnt/β-catenin pathway. This study offers a dual theoretical foundation for SUMOylation-targeted therapy and personalized prognostic evaluation. The studies featured in this topic collectively encompass multiple dimensions, ranging from fundamental mechanisms to translational applications, underscoring the significance of integrated multi-strategy interventions in PDAC treatment. Each article not only presents novel experimental evidence but also expands therapeutic perspectives. Whether through the diversification of immune cell types, the application of cytokine engineering, multi-target regulation via natural compounds, or mechanistic insights at the epigenetic level, these contributions reflect the field's diversity and innovative vitality. The studies featured in this Topic collectively cover multiple dimensions—from fundamental mechanisms to translational applications—highlighting the importance of combined multi-strategy interventions in PDAC treatment. Each article not only presents novel experimental evidence but also broadens therapeutic perspectives. Whether through the expansion of immune cell types, the application of cytokine engineering, multi-target regulation via natural compounds, or mechanistic insights at the epigenetic level, these contributions reflect the diversity and innovative vitality of the...
- 10 October 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1705678
Open AccessEditorial: Drug development for pancreatic cancer: novel targets, drug candidates and mechanisms
Pancreatic ductal adenocarcinoma (PDAC), the most prevalent subtype of pancreatic cancer, constitutes approximately 90% of all pancreatic cancer cases. It is recognized as one of the most aggressive malignancies globally, with a five-year survival rate persistently around 12%[1]. The absence of early specific symptoms and effective screening methods results in over 80% of patients being diagnosed at an advanced stage, frequently with local invasion or distant metastasis, thereby significantly limiting treatment options and contributing to a poor prognosis[2]. This challenging scenario highlights the urgent necessity to enhance our understanding of the biological mechanisms underlying PDAC and to develop innovative therapeutic strategies. While engineered T cell therapy has demonstrated significant success in treating hematologic malignancies, its application in PDAC remains fraught with substantial challenges[3]. These include an immunosuppressive microenvironment, tumor antigen heterogeneity, and inadequate T cell infiltration coupled with functional exhaustion. Moreover, PDAC treatment is hindered by several factors: a highly heterogeneous genomic landscape, a complex tumor microenvironment (TME), a persistently immunosuppressive state, and metabolic reprogramming mechanisms, all of which contribute to therapy resistance. Addressing these challenges necessitates interdisciplinary collaboration and the development of integrated, multi-dimensional interventional strategies—this is the primary research focus that this Research Topic seeks to advance. This collection of studies presents four pioneering investigations that illuminate the biological characteristics and therapeutic strategies of PDAC from diverse perspectives. These studies not only advance the understanding of disease mechanisms but also investigate novel interventions with translational potential, including immune cell engineering, natural product screening, and epigenetic regulation. Notably, the research conducted by Zhu et al. transcends traditional αβ T cell approaches by concentrating on the application of γδ T cells and natural killer T (NKT) cells in PDAC immunotherapy. Utilizing a mesothelin/CD3 bispecific antibody (BsAb), the authors demonstrate that these cells exhibit significantly enhanced tumor-killing activity both in vitro and in vivo, while substantially reducing the release of inflammatory cytokines such as IL-6 and IL-1β. This reduction in cytokine release mitigates the toxicities commonly associated with conventional αβ T cell-based therapies. Consequently, this study broadens the spectrum of cellular immunotherapy options and provides new pathways for enhancing treatment safety. Chen et al. tackle the issue of CAR-T cell exhaustion in PDAC through a novel strategy involving the co-expression of the IL-15/IL-15Rα complex (IL15C). This approach activates the JAK3/STAT5 signaling pathway, thereby significantly enhancing the proliferative capacity and anti-apoptotic characteristics of NKG2D-CAR T cells. The engineered cells exhibit a marked reduction in the expression of exhaustion markers, such as PD-1 and TIM-3, and preferentially differentiate into central memory T cells, leading to more sustained tumor control in vivo. This innovative strategy offers a valuable framework for optimizing CAR-T cell therapy in the context of solid tumors. In parallel, although Shao et al. conducted their investigation within a lung cancer model, their comprehensive research methodology offers substantial insights for PDAC drug development. By integrating network pharmacology, molecular docking, and functional validation, the researchers elucidate the anti-tumor mechanisms of cyclomorusin, an active compound derived from the traditional Chinese medicine Cortex Mori. This compound exerts its effects by inhibiting the PI3K/AKT/mTOR signaling pathway. The study highlights the contemporary scientific relevance of compounds derived from traditional medicine and provides a theoretical basis for the development of natural products targeting pancreatic ductal adenocarcinoma. Wang et al. explore the role of protein SUMOylation in PDAC and develop a prognostic scoring system (Sscore) based on SUMO substrate-encoding genes, including CDK1, AHNAK2, and SAFB. This model demonstrates efficacy in predicting patient survival and shows associations with genomic instability, immune infiltration, and drug sensitivity. Notably, through functional experiments, the authors identify SAFB2 as a novel tumor suppressor that impedes PDAC progression by inhibiting the Wnt/β-catenin pathway. This study offers a dual theoretical foundation for SUMOylation-targeted therapy and personalized prognostic evaluation. The studies featured in this topic collectively encompass multiple dimensions, ranging from fundamental mechanisms to translational applications, underscoring the significance of integrated multi-strategy interventions in PDAC treatment. Each article not only presents novel experimental evidence but also expands therapeutic perspectives. Whether through the diversification of immune cell types, the application of cytokine engineering, multi-target regulation via natural compounds, or mechanistic insights at the epigenetic level, these contributions reflect the field's diversity and innovative vitality. The studies featured in this Topic collectively cover multiple dimensions—from fundamental mechanisms to translational applications—highlighting the importance of combined multi-strategy interventions in PDAC treatment. Each article not only presents novel experimental evidence but also broadens therapeutic perspectives. Whether through the expansion of immune cell types, the application of cytokine engineering, multi-target regulation via natural compounds, or mechanistic insights at the epigenetic level, these contributions reflect the diversity and innovative vitality of the...
- Open Access
- 5 November 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15  (11) , 1-12
OTUB1 regulation of ferroptosis and the protective role of ferrostatin-1 in lupus nephritis
Lupus nephritis (LN) is a prevalent and severe manifestation of systemic lupus erythematosus (SLE), leading to significant morbidity and mortality. OTUB1, a deubiquitinating enzyme, has emerged as a potential therapeutic target due to its role in cellular protection and regulation of ferroptosis, a form of cell death linked to LN. Our study revealed significantly reduced OTUB1 expression in the glomeruli of LN patients and podocytes, correlated with disease severity. CRISPR/Cas9-mediated OTUB1 knockout in podocytes resulted in pronounced injury, indicated by decreased levels of nephrin and podocin. Ferrostatin-1 treatment effectively mitigated this injury, restoring SLC7A11 expression and significantly reducing MDA levels, Fe2+ levels, BODIPY C11 expression, and normalized cysteine and glutathione expression. In the MRL/lpr mouse model, Ferrostatin-1 significantly improved renal function decreased proteinuria, and ameliorated renal histopathological changes, including reduced glomerular endothelial swelling, mesangial cell proliferation, and leukocyte infiltration. These results underscore the protective role of Ferrostatin-1 in modulating the pathogenesis of LN. OTUB1 plays a crucial protective role against podocyte injury in LN by regulating ferroptosis. Ferrostatin-1 effectively mitigates podocyte damage induced by OTUB1 deficiency, suggesting that targeting ferroptosis could be a promising therapeutic strategy for LN.
- 5 November 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15  (11) , 1-12
Open AccessOTUB1 regulation of ferroptosis and the protective role of ferrostatin-1 in lupus nephritis
Lupus nephritis (LN) is a prevalent and severe manifestation of systemic lupus erythematosus (SLE), leading to significant morbidity and mortality. OTUB1, a deubiquitinating enzyme, has emerged as a potential therapeutic target due to its role in cellular protection and regulation of ferroptosis, a form of cell death linked to LN. Our study revealed significantly reduced OTUB1 expression in the glomeruli of LN patients and podocytes, correlated with disease severity. CRISPR/Cas9-mediated OTUB1 knockout in podocytes resulted in pronounced injury, indicated by decreased levels of nephrin and podocin. Ferrostatin-1 treatment effectively mitigated this injury, restoring SLC7A11 expression and significantly reducing MDA levels, Fe2+ levels, BODIPY C11 expression, and normalized cysteine and glutathione expression. In the MRL/lpr mouse model, Ferrostatin-1 significantly improved renal function decreased proteinuria, and ameliorated renal histopathological changes, including reduced glomerular endothelial swelling, mesangial cell proliferation, and leukocyte infiltration. These results underscore the protective role of Ferrostatin-1 in modulating the pathogenesis of LN. OTUB1 plays a crucial protective role against podocyte injury in LN by regulating ferroptosis. Ferrostatin-1 effectively mitigates podocyte damage induced by OTUB1 deficiency, suggesting that targeting ferroptosis could be a promising therapeutic strategy for LN.
- Open Access
- 23 August 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13  (8) , 1-9
CD36 aggravates podocyte injury by activating NLRP3 inflammasome and inhibiting autophagy in lupus nephritis
A major cause of proteinuria in lupus nephritis (LN) is podocyte injury, and determining potential therapeutic targets to prevent podocyte injury is important from a clinical perspective in the treatment of LN. CD36 is involved in podocyte injury in several glomerulopathies and was reported to be a vital candidate gene in LN. Here, we determined the role of CD36 in the podocyte injury of LN and the underlying mechanisms. We observed that CD36 and NLRP3 (NLR family pyrin domain containing 3) were upregulated in the podocytes of lupus nephritis patients and MRL/lpr mice with renal impairment. In vitro, CD36, NLRP3 inflammasome, and autophagy were elevated accompanied with increased podocyte injury stimulated by IgG extracted from lupus nephritis patients compared that from healthy donors. Knocking out CD36 with the CRISPR/cas9 system decreased the NLRP3 inflammasome levels, increased the autophagy levels and alleviated podocyte injury. By enhancing autophagy, NLRP3 inflammasome was decreased and podocyte injury was alleviated. These results demonstrated that, in lupus nephritis, CD36 promoted podocyte injury by activating NLRP3 inflammasome and inhibiting autophagy by enhancing which could decrease NLRP3 inflammasome and alleviate podocyte injury.
- 23 August 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13  (8) , 1-9
Open AccessCD36 aggravates podocyte injury by activating NLRP3 inflammasome and inhibiting autophagy in lupus nephritis
A major cause of proteinuria in lupus nephritis (LN) is podocyte injury, and determining potential therapeutic targets to prevent podocyte injury is important from a clinical perspective in the treatment of LN. CD36 is involved in podocyte injury in several glomerulopathies and was reported to be a vital candidate gene in LN. Here, we determined the role of CD36 in the podocyte injury of LN and the underlying mechanisms. We observed that CD36 and NLRP3 (NLR family pyrin domain containing 3) were upregulated in the podocytes of lupus nephritis patients and MRL/lpr mice with renal impairment. In vitro, CD36, NLRP3 inflammasome, and autophagy were elevated accompanied with increased podocyte injury stimulated by IgG extracted from lupus nephritis patients compared that from healthy donors. Knocking out CD36 with the CRISPR/cas9 system decreased the NLRP3 inflammasome levels, increased the autophagy levels and alleviated podocyte injury. By enhancing autophagy, NLRP3 inflammasome was decreased and podocyte injury was alleviated. These results demonstrated that, in lupus nephritis, CD36 promoted podocyte injury by activating NLRP3 inflammasome and inhibiting autophagy by enhancing which could decrease NLRP3 inflammasome and alleviate podocyte injury.
- Open Access
- 15 February 2021
- Published by Oxford University Press (OUP) in Toxicology Research
- Vol. 10  (2) , 183-191
Toxicological evaluation of aqueous extract of the traditional Chinese formula Qing Hao Gan Cao
Qing Hao Gan Cao (QHGC), a Chinese medicinal formula containing Artemisia annua and Glycyrrhizae Radix et Rhizoma, has been used to treat sunstroke and as an antiviral agent for more than 800 years. It has not previously been subject to a toxicological safety evaluation in acute and subacute (28 days) studies. Therefore, the acute and subacute toxicity of an aqueous extract of QHGC were evaluated in vivo. For the QHGC preparation, the botanical raw materials were crushed into pieces and mixed in the ratio of 10:1 in distilled water for 12 h, then boiling three times for 2 h each time. The three decoctions were mixed and filtered, then spray-dried with hot air at 160°C for 30 min, and stored at room temperature. For the acute toxicity test, 72.0 g/kg of QHGC extract was administered by gavage to male and female mice. Body weight, general observations, and autopsy results were recorded. No mortality or toxicity signs were observed during the studies. For the subacute toxicity test, 4.0, 8.0, or 16.0 g/kg/day of QHGC extract was administered to rats for 28 days. General observations and mortality, body weight, biochemical and hematological parameters, organ weight, and pathological morphology were analyzed. The acute and subacute toxicity studies did not show significant changes in body weight, general observations, hematology and biochemical parameters, organ weight, and liver, spleen, stomach, duodenum, testis, ovary, lung, heart, and kidney histopathological analyses. The consumption of QHGC aqueous extract can be considered safe within the conditions of this study.
- 15 February 2021
- Published by Oxford University Press (OUP) in Toxicology Research
- Vol. 10  (2) , 183-191
Open AccessToxicological evaluation of aqueous extract of the traditional Chinese formula Qing Hao Gan Cao
Qing Hao Gan Cao (QHGC), a Chinese medicinal formula containing Artemisia annua and Glycyrrhizae Radix et Rhizoma, has been used to treat sunstroke and as an antiviral agent for more than 800 years. It has not previously been subject to a toxicological safety evaluation in acute and subacute (28 days) studies. Therefore, the acute and subacute toxicity of an aqueous extract of QHGC were evaluated in vivo. For the QHGC preparation, the botanical raw materials were crushed into pieces and mixed in the ratio of 10:1 in distilled water for 12 h, then boiling three times for 2 h each time. The three decoctions were mixed and filtered, then spray-dried with hot air at 160°C for 30 min, and stored at room temperature. For the acute toxicity test, 72.0 g/kg of QHGC extract was administered by gavage to male and female mice. Body weight, general observations, and autopsy results were recorded. No mortality or toxicity signs were observed during the studies. For the subacute toxicity test, 4.0, 8.0, or 16.0 g/kg/day of QHGC extract was administered to rats for 28 days. General observations and mortality, body weight, biochemical and hematological parameters, organ weight, and pathological morphology were analyzed. The acute and subacute toxicity studies did not show significant changes in body weight, general observations, hematology and biochemical parameters, organ weight, and liver, spleen, stomach, duodenum, testis, ovary, lung, heart, and kidney histopathological analyses. The consumption of QHGC aqueous extract can be considered safe within the conditions of this study.
- 1 February 2020
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 248, 112324
Toxicological safety evaluation in acute and 28-day studies of aqueous extract from Bei-Qi-Wu-Jia formula
- 1 February 2020
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 248, 112324
Toxicological safety evaluation in acute and 28-day studies of aqueous extract from Bei-Qi-Wu-Jia formula
- RetractedOpen Access
- 29 August 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7  (1) , 1-13
RETRACTED ARTICLE: A novel chalcone derivative S17 induces apoptosis through ROS dependent DR5 up-regulation in gastric cancer cells
A new series of etherification chalcone derivatives were designed and synthesized through Willimison etherification and Claisen-Schmidt condensation. Among them, compound 2-c which was given chemical name of S17 , has been successfully screened out as the most potent one on gastric cancer cell line(MGC803) through the investigation for their effects against the growth of five cancer cell lines (EC109, HepG2, MCF7, MGC803, SKNSH). S17 exhibited strong anti-proliferative activity on other two gastric cancer cells (HGC27 and SGC7901), but less cytotoxicity to non-malignant gastric epithelial cells GES1. S17 potently killed gastric cancer cells with causing modulation of Bcl-2 family proteins and activation of caspase 9/3 cascade. S17 also up-regulated DR5 expression and DR5 knockdown partially reversed S17 -induced apoptosis, caspase activation and MMP decrease. S17 robustly induced generation of ROS with Keap/Nrf2 pathway activated and the application of ROS scavenger N-acetyl cysteine (NAC) completely blocked these effects by S17 in MGC803 cells. Intraperitoneal administration of S17 significantly inhibited the growth of MGC803 cells in vivo in a xenograft mouse model without observed toxicity. These results indicated that S17 is a leadbrominated chalcone derivate and deserves further investigation for prevention and treatment of gastric cancer.
- 29 August 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7  (1) , 1-13
RetractedOpen AccessRETRACTED ARTICLE: A novel chalcone derivative S17 induces apoptosis through ROS dependent DR5 up-regulation in gastric cancer cells
A new series of etherification chalcone derivatives were designed and synthesized through Willimison etherification and Claisen-Schmidt condensation. Among them, compound 2-c which was given chemical name of S17 , has been successfully screened out as the most potent one on gastric cancer cell line(MGC803) through the investigation for their effects against the growth of five cancer cell lines (EC109, HepG2, MCF7, MGC803, SKNSH). S17 exhibited strong anti-proliferative activity on other two gastric cancer cells (HGC27 and SGC7901), but less cytotoxicity to non-malignant gastric epithelial cells GES1. S17 potently killed gastric cancer cells with causing modulation of Bcl-2 family proteins and activation of caspase 9/3 cascade. S17 also up-regulated DR5 expression and DR5 knockdown partially reversed S17 -induced apoptosis, caspase activation and MMP decrease. S17 robustly induced generation of ROS with Keap/Nrf2 pathway activated and the application of ROS scavenger N-acetyl cysteine (NAC) completely blocked these effects by S17 in MGC803 cells. Intraperitoneal administration of S17 significantly inhibited the growth of MGC803 cells in vivo in a xenograft mouse model without observed toxicity. These results indicated that S17 is a leadbrominated chalcone derivate and deserves further investigation for prevention and treatment of gastric cancer.